BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35143036)

  • 1. A rare case of a giant prolactinoma with atypical histological features: 5 years of follow-up.
    Vasilakis IA; Paltoglou G; Gavra M; Charmandari E
    Hormones (Athens); 2022 Jun; 21(2):323-327. PubMed ID: 35143036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Atypical presentation of a giant prolactinoma in a 15-year-old boy].
    Vaiani E; Morales C; Soto F; Blanco Y; Rugilo C; Ciaccio M; Belgorosky A
    Arch Argent Pediatr; 2018 Apr; 116(2):e325-e330. PubMed ID: 29557627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience.
    Kontbay T; Şıklar Z; Özsu E; Uyanık R; Bilici E; Ceran A; Berberoğlu M
    Turk J Pediatr; 2022; 64(5):892-899. PubMed ID: 36305439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Giant prolactinomas presenting as skull base tumors.
    Minniti G; Jaffrain-Rea ML; Santoro A; Esposito V; Ferrante L; Delfini R; Cantore G
    Surg Neurol; 2002 Feb; 57(2):99-103; discussion 103-4. PubMed ID: 11904200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?
    Phillips J; East HE; French SE; Melcescu E; Hamilton RD; Nicholas WC; Fratkin JF; Parent AD; Luzardo G; Koch CA
    Hormones (Athens); 2012; 11(4):477-82. PubMed ID: 23422771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive Giant Prolactinoma.
    Alkhaibary A; Alharbi A; Khairy S
    World Neurosurg; 2024 Jan; 181():21-22. PubMed ID: 37827431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Giant prolactinoma, germline BRCA1 mutation, and depression: a case report.
    Bettencourt-Silva R; Queirós J; Pereira J; Carvalho D
    J Med Case Rep; 2018 Dec; 12(1):360. PubMed ID: 30518416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men.
    Shimon I; Benbassat C; Hadani M
    Eur J Endocrinol; 2007 Feb; 156(2):225-31. PubMed ID: 17287412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of hypogonadism in a male patient with a giant prolactinoma: a clinical paradox.
    Tamagno G; Daly AF; Deprez M; Vroonen L; Andris C; Martin D; Beckers A
    Ann Endocrinol (Paris); 2008 Feb; 69(1):47-52. PubMed ID: 18082643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten-year follow-up of a giant prolactinoma.
    Fernandes V; Santos MJ; Almeida R; Marques O
    BMJ Case Rep; 2015 Nov; 2015():. PubMed ID: 26590188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature.
    Berwaerts J; Verhelst J; Abs R; Appel B; Mahler C
    J Endocrinol Invest; 2000 Jun; 23(6):393-8. PubMed ID: 10908167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Giant prolactinomas in adolescence: an uncommon cause of blindness.
    Semple P; Fieggen G; Parkes J; Levitt N
    Childs Nerv Syst; 2007 Feb; 23(2):213-7. PubMed ID: 16983572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Giant prolactinoma presented as unilateral exophthalmos in a prepubertal boy: response to cabergoline.
    Krassas GE; Pontikides N; Kaltsas T
    Horm Res; 1999; 52(1):45-8. PubMed ID: 10640900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid improvement in visual loss with cabergoline treatment in a giant prolactinoma case: 5 years survey.
    Tasan E; Hanimoglu H; Turgut S; Ilhan MM; Evran S; Kaynar MY
    Neuro Endocrinol Lett; 2015; 36(1):28-30. PubMed ID: 25789596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GIANT PROLACTINOMA. A CASE REPORT.
    Šulavíková Z; Krásnik V
    Cesk Slov Oftalmol; 2023; 79(3):143-148. PubMed ID: 37344216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Giant prolactinomas, a detailed analysis of 196 adult cases.
    Lisa B; Arno V; Christophe B; Heyning Paul V; Carlien H
    Pituitary; 2023 Oct; 26(5):529-537. PubMed ID: 37544978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
    Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
    Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
    Colao A; Loche S; Cappa M; Di Sarno A; Landi ML; Sarnacchiaro F; Facciolli G; Lombardi G
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2777-80. PubMed ID: 9709946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.